Entera Bio Ltd. (ENTX) intrinsic value & 10-year financials
Entera Bio Ltd. (ENTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 29.8% a year to $42.0K, with an average return on invested capital of 679.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.68
- Market cap
- $123.8M
- Revenue (FY2025)
- $42.0K
- Revenue growth (10-yr CAGR)
- -29.8%
- ROIC (10-yr avg)
- 679.2%
- Free cash flow (FY2025)
- -$7.5M
ENTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $42.0K | -$11.4M | $0.25 | -$7.5M | -27450.0% | -399.3% |
| FY2024 | $181.0K | -$9.5M | $0.25 | -$6.8M | -5295.6% | 2242.1% |
| FY2023 | $0 | -$8.9M | $0.31 | -$7.3M | — | 1907.9% |
| FY2022 | $134.0K | -$13.1M | $0.45 | -$12.5M | -9714.2% | 943.6% |
| FY2021 | $571.0K | -$12.2M | $0.47 | -$9.1M | -2139.6% | 798.8% |
| FY2020 | $365.0K | -$11.2M | $0.55 | -$10.6M | -3059.7% | 1329.5% |
| FY2019 | $236.0K | -$10.8M | $0.89 | -$9.0M | -4853.4% | -90.4% |
| FY2018 | $500.0K | -$10.3M | $1.31 | -$9.9M | -2172.2% | 26.1% |
| FY2017 | — | -$11.2M | $2.49 | -$4.6M | — | 28.4% |
| FY2016 | — | -$1.2M | $0.78 | -$3.2M | — | 4.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Entera Bio Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Entera Bio Ltd. has earned high returns on invested capital, averaging 15.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Entera Bio Ltd. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Entera Bio Ltd. is modeled at -11.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3.29 per share.